Login to Your Account



Top-Line in Head-and-Neck Cancer

Wall Street 'Reolysin' Value; Oncolytics Soars on Phase III

By Randy Osborne
Staff Writer

Friday, December 14, 2012

Stock buyers hardly cared that Oncolytics Biotech Inc.'s early Phase III results with Reolysin, its reovirus variant for head and neck cancer, lacked survival data and slipped on part of its endpoint – the rest was just too good.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription